NCT00725803View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

March 31, 2009

Conditions
HCV Infection
Interventions
DRUG

GS-9450

GS-9450 capsules administered orally once daily

DRUG

GS-9450 Placebo

Placebo to match GS-9450 administered orally once daily

Trial Locations (11)

Unknown

Anaheim

Washington D.C.

Orlando

Dallas

San Antonio

Frankfurt

Hamburg

Hanover

Mainz

Würzburg

Amsterdam

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00725803 - Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV | Biotech Hunter | Biotech Hunter